Zacks Investment Research on MSN
CAPR updates FDA on Deramiocel BLA, plans HOPE-3 CSR filing in February
Capricor Therapeutics CAPR recently provided a regulatory update on its Biologics License Application (BLA) for Deramiocel, following recent interactions with the FDA. After reviewing topline data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results